Details:
- Condition: Advanced or metastatic urothelial carcinoma (mUC).
- Requirement: The presence of FGFR3 or FGFR2 genetic alterations must be confirmed in tumor specimens before starting treatment.
- Administration: Tablets are swallowed whole and can be taken with or without food.
- Dosage: The appropriate dose is determined by an oncologist based on specific criteria and patient response.
Reviews
There are no reviews yet.